TNF-alpha antagonists for the treatment of Crohn's disease.

@article{Kam2000TNFalphaAF,
  title={TNF-alpha antagonists for the treatment of Crohn's disease.},
  author={Lori Y Kam and Stephan Raoul Targan},
  journal={Expert opinion on pharmacotherapy},
  year={2000},
  volume={1 4},
  pages={615-22}
}
New medical therapies that inhibit the bioactivity of TNF-alpha represent a major breakthrough in the treatment of Crohn's disease (CD). Anti-TNF-alpha, monoclonal, chimeric antibody (infliximab) is now FDA approved for use in patients with active CD. Other investigational drugs that also inhibit TNF-alpha activity include new 'humanised' anti-TNF-alpha antibodies (CDP571), thalidomide, new analogues of thalidomide, and TNF-alpha receptor fusion proteins. This review will summarise the key… CONTINUE READING